Country: Canada
Language: English
Source: Health Canada
GRASS POLLEN ALLERGEN EXTRACT
STALLERGENES CANADA INC
V01AA02
GRASS POLLEN
300UNIT
TABLET
GRASS POLLEN ALLERGEN EXTRACT 300UNIT
SUBLINGUAL
28/30/90
Prescription
ALLERGENIC EXTRACTS
Active ingredient group (AIG) number: 0153132002; AHFS:
APPROVED
2015-04-01
_ _ _Page 1 of 39_ PRODUCT MONOGRAPH PR ORALAIR Grass Pollen Allergen Extract 100 IR and 300 IR Sublingual Tablets Allergenic Substance Stallergenes Canada Inc. 1215 North Service Road West, Suite B Oakville, ON L6M 2W2 Canada Date of Preparation: September 6, 2016 APPROVAL DATE: NOVEMBER 18, 2016 SUBMISSION CONTROL NO: 192653 _ _ _Page 2 of 39_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................4 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................5 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS .................................................................................................19 DOSAGE AND ADMINISTRATION..............................................................................20 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................22 STORAGE AND STABILITY ..........................................................................................23 SPECIAL HANDLING INSTRUCTIONS .......................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................23 PART II: SCIENTIFIC INFORMATION ...............................................................................24 PHARMACEUTICAL INFORMATION ..........................................................................24 CLINICAL TRIALS ..................................... Read the complete document